Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.

MLA

Fennell, Dean A., et al. “Rucaparib in Patients with BAP1-Deficient or BRCA1-Deficient Mesothelioma (MiST1): An Open-Label, Single-Arm, Phase 2a Clinical Trial.” Lancet Respiratory Medicine, vol. 9, no. 6, June 2021, pp. 593–600. EBSCOhost, https://doi.org/10.1016/S2213-2600(20)30390-8.

APA

Fennell, D. A., King, A., Mohammed, S., Branson, A., Brookes, C., Darlison, L., Dawson, A. G., Gaba, A., Hutka, M., Morgan, B., Nicholson, A., Richards, C., Wells-Jordan, P., Murphy, G. J., & Thomas, A. (2021). Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respiratory Medicine, 9(6), 593–600. https://doi.org/10.1016/S2213-2600(20)30390-8

Chicago

Fennell, Dean A, Amy King, Seid Mohammed, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, et al. 2021. “Rucaparib in Patients with BAP1-Deficient or BRCA1-Deficient Mesothelioma (MiST1): An Open-Label, Single-Arm, Phase 2a Clinical Trial.” Lancet Respiratory Medicine 9 (6): 593–600. doi:10.1016/S2213-2600(20)30390-8.